Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

: justify; mso-layout-grid-align: none"> More details on the trial

The Jikei Heart Study1 was a multi-center controlled clinical trial with a prospective randomized open-label blinded endpoint (PROBE) design. It was conducted by the Jikei University School of Medicine in Tokyo in 3,081 people aged 20 to 79 years with high blood pressure, ischemic heart disease or congestive heart failure. There were no significant differences in blood pressure or heart rate between the treatment groups.

The cardiovascular events counted in the combined primary endpoint of cardiovascular mortality and morbidity were: new or recurrent stroke or transient ischemic attack, hospitalization for congestive heart failure or angina pectoris, heart attack, aortic dissection, lower limb arterial obstruction, doubling of serum creatinine, or transition to dialysis.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as “can offer” or similar expressions, or by express or implied disc
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Post Your Comments:
(Date:5/28/2015)... FORT WORTH, Texas , May 28, 2015 /PRNewswire/ ... defines and segments the concerned market with analysis and ... million in 2014 and is estimated to reach $1,177.8 ... 2014 to 2019. Browse through the TOC ... the industry trends and segments, with help of various ...
(Date:5/28/2015)... Colo. , May 28, 2015  Array BioPharma ... encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the ... which will be held May 29 – June 2, ... three products are currently advancing in a total of ... from both the NEMO (binimetinib monotherapy in NRAS mutant ...
(Date:5/28/2015)... , May 28, 2015  Pharmaceutic Labs announces ... under section 503B of the FDA,s Drug Quality ... the company is subject to Current Good Manufacturing ... medications according to the highest standards of CGMP ... 211. To continuously comply with FDA regulations and ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... LAS VEGAS, BASKING RIDGE, N.J., and TOTOWA, N.J., Jan. ... (CES), Verizon Wireless and VectraCor, Inc. today said the ... booth (Las Vegas Convention Center, South Hall, Booth #30259).  ... ambulatory cardiac monitor that incorporates an electrocardiogram (ECG) amplifier ...
... 10, 2012  Wells Pharmacy Network President, Robert L. ... opening of Wells Pharmacy,s corporate headquarters. Located in ... pharmacy is focused on serving the unique needs ... Compounding combines the art and skill of pharmacy with the ...
Cached Medicine Technology:Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 2Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 3"Wells Pharmacy Network" a Premier Compounding Pharmacy Focused on Serving the Unique Needs of the Medical and Veterinarian Communities Opens in Wellington 2
(Date:5/28/2015)... Ross A. Clevens, MD, FACS, Brevard’s ... Beard as the new marketing director for Clevens Face ... all marketing and promotional events for the practice. Beard ... developing compelling marketing strategies to achieve targeted results. Prior ... as guest communication manager at the Walt Disney World ...
(Date:5/28/2015)... The Paw Project, an ... billboard intended to educate the Oregon public about the ... intersection of Market Street and Park Avenue in Salem, ... for De-clawing Cats, Raise Your Hand,” depicts a human ... providing a graphic and anatomically-correct representation of the declaw ...
(Date:5/28/2015)... May 28, 2015 Altima Technologies, ... Device Library for documenting and diagramming data center ... for the following product lines: , Manufacturer ... 5500, Chatsworth Products N-Series TeraFrame Cabinet, Middle Atlantic ... Eclipse, Fore Systems ForeRunner, Marantz America MM Series, ...
(Date:5/28/2015)... May 28, 2015 Workers’ compensation costs per ... state, a recent study by the Workers Compensation Research ... a three-year period. , The WCRI study, CompScope™ Benchmarks ... workers missed seven days or more of work with those ... average 2011 Michigan claim was 4 percent lower than similar ...
(Date:5/28/2015)... 2015 More than 300 locations of ... money to help the Muscular Dystrophy Association save and ... related life-threatening diseases that limit muscle strength and mobility ... , From June 1 to June 30, sweetFrog associates ... opportunity to help send local children affected by neuromuscular ...
Breaking Medicine News(10 mins):Health News:Clevens Face and Body Specialists Welcomes Teresa Beard as Marketing Director 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3
... competition behind almost 60% of cases, study finds ... high school athletes in the United States are ... , The researchers looked at football, soccer, volleyball, ... injuries accounted for just 8 percent of all ...
... study published in Journal of the American Geriatrics Society ... populations may be associated with cognitive decline. The study examined ... drug used to treat a variety of disorders that include ... aged 65 years or older with high blood pressure. ...
... BIRMINGHAM, Ala., Jan. 26 HealthSouth,Corporation (NYSE: HLS ... Global High Yield & Leveraged Finance Conference on Feb. 2-4, ... Chief Financial Officer John Workman will be speaking on,Tuesday, Feb. ... live and may,be accessed via the Investor Information section on ...
... while crossing streets are at a higher risk for injuries ... University of Alabama at Birmingham (UAB) in a new study ... . , "Cell phones clearly offer convenience and safeguards to ... when children attempt to multitask while conversing on the cell ...
... people have the right to clean air. Action ... may soon be able to breathe easier, said Dr. ... Alliance for Hispanic Health, the nation,s leading Hispanic health ... a Presidential Memorandum to the Environmental Protection Agency (EPA) ...
... /PRNewswire/ -- Alma Lasers Ltd. ("Alma"), ... devices, announced today the FDA clearance and immediate ... is the fifth module available on the Accent(TM) ... FDA clearance for "the temporary reduction in the ...
Cached Medicine News:Health News:HS Sports Shoulder Injuries More Likely in Boys 2Health News:Common medication associated with cognitive decline in elderly 2Health News:Cell phones dangerous for child pedestrians, UAB study finds 2Health News:Statement on Presidential Memorandum to EPA to Review Lifting of Ban on California Clean Car Standard 2
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
ELP 40- 8 Way Head Strip Plate Washer....
Finstruments 96 well washer and Cellwasher. Multi-function with touch programmable display....
The Finstrip 4 is an effective and reliable microplate washer offering high performance, simplicity and ease of use....
Medicine Products: